Rakesh Patel, DO
Physical Medicine & Rehabilitation · Altoona, PANPI 1114958618
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 5 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) accounts for 80.6% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $371, more than ten times the $19 reported in 2021.
Across 5 payments — averaging $92.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$371
- Bioventus LLC$70
- Zealand Pharma US, Inc.$19
What the payments were for
- Food & beverage$460100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $371 |
| Bioventus LLC | 1 | $70 |
| Zealand Pharma US, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$371
How this compares
$460 in reported general payments places this provider in the 65th percentile of 550 physical medicine & rehabilitation providers in Pennsylvania.
See all physical medicine & rehabilitation providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 84 | $46,489 |
| JardianceEmpagliflozin | 33 | $18,765 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $15,154 |
| XareltoRivaroxaban | 11 | $5,685 |
| BrilintaTicagrelor | 13 | $5,462 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $2,185 |
| Enoxaparin Sodium | 26 | $1,880 |
| Pantoprazole Sodium | 164 | $1,501 |
| Humalog Kwikpen U-100Insulin Lispro | 14 | $1,415 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 16 | $1,408 |
| Midodrine Hcl | 30 | $1,311 |
| Atorvastatin Calcium | 160 | $1,287 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $926 |
| Potassium Chloride | 70 | $917 |
| Gabapentin | 91 | $715 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Altoona
- David BozakAltoona$9K
- Jeffery RoweKing Of Prussia$1.9M
- Michael SaulinoElkins Park$425K
- Huaguang QuChalfont$356K
- Alberto EsquenaziPhiladelphia$305K
- Mitchell PaulinPaoli$229K
- Kimberly HeckertPhiladelphia$119K
- David LichtenReading$117K
- Gay WilcherRidley Park$81K
- Jessica MulhernPaoli$79K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.